Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time.
Catalyst Biosciences’ management team will provide an overview of the Company’s recently introduced complement programs as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen and marzeptacog alfa (activated) (MarzAA), the company’s late-stage hemostasis asset.
About Catalyst Biosciences, a Protease Medicines company
Creating Next-Gen Collaborative Post-Pandemic Work Environments
Exhibit Hall Open